DK2189537T3 - Detektion og behandling af skizofreni - Google Patents

Detektion og behandling af skizofreni

Info

Publication number
DK2189537T3
DK2189537T3 DK08792016.1T DK08792016T DK2189537T3 DK 2189537 T3 DK2189537 T3 DK 2189537T3 DK 08792016 T DK08792016 T DK 08792016T DK 2189537 T3 DK2189537 T3 DK 2189537T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
detection
treatment
Prior art date
Application number
DK08792016.1T
Other languages
English (en)
Inventor
Toshio Miyata
Makoto Arai
Masanari Itokawa
Original Assignee
Renascience Co Ltd
Tokyo Metropolitan Inst Medical Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renascience Co Ltd, Tokyo Metropolitan Inst Medical Science filed Critical Renascience Co Ltd
Application granted granted Critical
Publication of DK2189537T3 publication Critical patent/DK2189537T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08792016.1T 2007-08-20 2008-07-31 Detektion og behandling af skizofreni DK2189537T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007214047A JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療
PCT/JP2008/063803 WO2009025159A1 (ja) 2007-08-20 2008-07-31 統合失調症の検査および治療

Publications (1)

Publication Number Publication Date
DK2189537T3 true DK2189537T3 (da) 2014-10-27

Family

ID=40378067

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08792016.1T DK2189537T3 (da) 2007-08-20 2008-07-31 Detektion og behandling af skizofreni

Country Status (11)

Country Link
US (2) US8809329B2 (da)
EP (2) EP2662453A3 (da)
JP (1) JP5288365B2 (da)
CY (1) CY1115640T1 (da)
DK (1) DK2189537T3 (da)
ES (1) ES2515168T3 (da)
HR (1) HRP20140993T1 (da)
PL (1) PL2189537T3 (da)
PT (1) PT2189537E (da)
SI (1) SI2189537T1 (da)
WO (1) WO2009025159A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551426B2 (en) 2009-06-12 2013-10-08 Bioneer Corporation Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same
WO2011142460A1 (ja) * 2010-05-14 2011-11-17 財団法人東京都医学総合研究所 統合失調症の検出方法
CN102993191B (zh) * 2012-12-18 2015-05-27 苏州大学 一种含有吖内酯与吡唑啉酮的杂环手性化合物及其衍生物、合成方法及用途
WO2016031839A1 (ja) 2014-08-29 2016-03-03 株式会社プロジェクトＰｍ ピリドキサミン化合物及びチアミン化合物を組み合わせてなる医薬組成物
KR101796390B1 (ko) * 2015-07-24 2017-11-09 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
JP6924964B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
CN109982639A (zh) * 2017-07-07 2019-07-05 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
WO2019008996A1 (ja) * 2017-07-07 2019-01-10 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
EP3760724A4 (en) 2018-02-27 2022-01-05 Kikkoman Corporation NEW ENZYME AND METHOD FOR THE DETERMINATION OF PENTOSIDINE USING THE SAME
JPWO2021039611A1 (da) * 2019-08-27 2021-03-04

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) * 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
JP3507884B2 (ja) 2000-03-07 2004-03-15 新潟大学長 遺伝子発現を指標とする統合失調症の客観的診断法
WO2002061065A2 (en) * 2001-01-31 2002-08-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Phosphorylated glyoxalase i and its use
JP2003038198A (ja) 2001-07-27 2003-02-12 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
JP2003212795A (ja) 2002-01-15 2003-07-30 Japan Science & Technology Corp 精神分裂病の診断薬
WO2004005935A1 (ja) 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
JP2004251865A (ja) 2003-02-19 2004-09-09 Takashi Muramatsu 統合失調症およびアルツハイマー病の検査薬
JP4143498B2 (ja) 2003-07-31 2008-09-03 独立行政法人科学技術振興機構 統合失調症の判定方法
KR20060123125A (ko) 2003-09-30 2006-12-01 상꾜 가부시키가이샤 테트라졸 고리 또는 티아졸리딘디온 고리를 갖는 페닐렌유도체
US20050249823A1 (en) 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
AU2004294435B2 (en) * 2003-12-05 2010-07-08 Kiyoshi Kurokawa Inhibitor of protein modification products formation
JP2005278490A (ja) 2004-03-29 2005-10-13 Japan Science & Technology Agency 統合失調症に関与する生物学的マーカーの判定方法およびその利用
JP5079503B2 (ja) 2005-06-07 2012-11-21 株式会社インバイオテックス ラジカルスカベンジャー及び活性酸素消去剤
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives

Also Published As

Publication number Publication date
US8809329B2 (en) 2014-08-19
PT2189537E (pt) 2014-10-30
US20120065198A2 (en) 2012-03-15
US20110028470A1 (en) 2011-02-03
HRP20140993T1 (hr) 2014-12-19
ES2515168T3 (es) 2014-10-29
EP2662453A3 (en) 2014-02-26
EP2189537A4 (en) 2010-08-11
CY1115640T1 (el) 2017-01-04
PL2189537T3 (pl) 2015-01-30
WO2009025159A1 (ja) 2009-02-26
US20140335517A1 (en) 2014-11-13
JP2009039088A (ja) 2009-02-26
EP2662453A2 (en) 2013-11-13
EP2189537A1 (en) 2010-05-26
JP5288365B2 (ja) 2013-09-11
EP2189537B1 (en) 2014-10-08
SI2189537T1 (sl) 2014-11-28

Similar Documents

Publication Publication Date Title
DK2189537T3 (da) Detektion og behandling af skizofreni
DK2114447T3 (da) Forebyggelse og behandling af subkliniks pcvd
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DK3067066T3 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK2264042T3 (da) Mikronisering af polyoler
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
DK2255184T3 (da) Serotonintransportergen og behandling af alkoholisme
DK2987487T3 (da) Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
DK2700786T3 (da) Modifikation af overførselspassage
DK2091673T3 (da) Elektromagnetisk behandling af kontaminerede materialer
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK2440253T3 (da) Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
BRPI0813681A2 (pt) Detecção de coproantígeno de nematelminto
DK2614832T3 (da) Diagnose og behandling af præeklampsi
DK2254598T3 (da) Kombination af alfa 7-nikotinagonister og antipsykotika
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK3150721T3 (da) Pankreascancermarkører og detekteringsfremgangsmåder